Evidence map›Paper›PMID 40734437›Full record

ArticleCurrent pharmaceutical biotechnology2026

Biotechnological and Pharmaceutical Application of β-galactosidase Stabilized on Surface-modified Silica Nanoparticles.

Shakeel Ahmed Ansari, Ahmed A Damanhory, Doha Zakaria Sija, Rukhsana Satar

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shakeel Ahmed AnsariDepartment of Biochemistry, Medicine Program, Batterjee Medical College, Jeddah, Saudi Arabia.ORCID 0000-0002-5630-8034
Ahmed A DamanhoryDepartment of Biochemistry, Medicine Program, Batterjee Medical College, Jeddah, Saudi Arabia.
Doha Zakaria SijaDepartment of Clinical Sciences, Medicine Program, Vision Colleges, Riyadh, Saudi Arabia.
Rukhsana SatarDepartment of Biophysiology, Division of Biochemistry, Medicine Program, Ibn Sina National Medical College, Jeddah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNanoparticles used in enzyme immobilization offer a high surface area- to-volume ratio, high chemical and thermal stability, and resistance to microbial attack.

methodsThe present investigation demonstrates the immobilization of Aspergillus oryzae β- galactosidase on silica nanoparticles via covalent binding. A greater yield of enzyme immobilization (89%) was attained on the developed nanobiocatalyst.

resultsIt was observed that the immobilized and soluble enzymes had optimal pH and temperature values of 50°C and 4.5, respectively. It was monitored that at pH 4.0, soluble β- galactosidase (SβG) exhibited 59% activity. However, the immobilized enzyme showed 92% activity under identical conditions. Similarly, 41% enzyme activity was retained at 70 °C by the free enzyme. Conversely, immobilized β-galactosidase (IβG) retained 70% activity under similar experimental conditions. Additionally, it was observed that at 5% galactose concentration, IβG showed 55% activity under one hour of incubation. However, under comparable experimental conditions, SβG showed 24% activity. DISCUSSION: It was observed that the immobilized enzyme was reusable, maintaining 90% of its activity even after five uses. The soluble enzyme demonstrated 62% and 70% lactose hydrolysis under the same conditions after 8 hours, while IβG demonstrated 74% and 85% lactose hydrolysis at 40°C and 50°C, respectively, in a controlled batch reactor experiment that was run for 10 hours.

conclusionHence, owing to the greater reusability (90% after 5th repeated use) and excellent conversion of lactose at higher temperatures, the developed nanosupport may be used to produce lactose-free dairy products in continuous reactors on a large scale in biotechnology industries.

Indexed as

beta-GalactosidaseEnzymes, ImmobilizedNanoparticlesSilicon DioxideAspergillus oryzaeBiotechnologyEnzyme StabilityGalactoseHydrogen-Ion ConcentrationHydrolysisLactoseSurface PropertiesTemperaturebeta-GalactosidaseEnzymes, ImmobilizedGalactoseLactoseSilicon DioxideAspergillus oryzaebiotechnological applicationshealthcaresilica nanoparticlessurface modificationβ-galactosidase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.